Amlodipine Besylate Market

The increasing prevalence of hypertension and rising demand for managing high blood pressure are driving the market growth.

Market CAGR for Amlodipine Besylate is being driven by the Increasing prevalence of hypertension and rising demand for managing high blood pressure.

One of the main factors motivating the market is lifestyle changes, diet factors, and the aging population that is growing fast and contributing to an increase in market share. Statistically, the CDC indicated that 691,095 deaths in the US were attributed to hypertension in 2021 as the primary or contributing diagnosis. Being under one in four adults with hypertension with poor control of their condition seems to be the most common case (22.5%, 27.0 million). This makes the demand for amlodipine besylate even more solid. In 2050, elderly people are expected to fill approximately 80% of the population of low and middle-tier economies. By 2020, those aged 60 years and above had surpassed the number of children of less than 5 years. The world's population over sixty years old by 2050 will reach a level that is almost twice as high as the level in 2015, which was 12%.

The growing need to manage high blood pressure has stimulated the demand for amlodipine besylate as the primary medication. As the report by the Centers for Disease Control and Prevention indicates, the percentage of men who have high blood pressure (50%) is higher compared to the percentage of women (44%). Black non-Hispanic Americans have a relatively higher incidence of high blood pressure (56%) as compared to non-Hispanic whites (48%), non-Hispanic Asians (46%), and Hispanics (39%).

As a result, it is anticipated that throughout the projection period, demand for the Amlodipine Besylate Market will increase due to the Increasing prevalence of hypertension and rising demand for managing high blood pressure. Thus, driving the Amlodipine Besylate Market revenue.

The aging population is another crucial factor influencing the Global Amlodipine Besylate Market Industry. As the global demographic shifts towards an older population, the incidence of chronic conditions, including hypertension, tends to increase. Older adults are more susceptible to cardiovascular diseases, necessitating effective management strategies. This demographic shift suggests that the market for Amlodipine Besylate will expand, as it is often prescribed for elderly patients. By 2035, the Global Amlodipine Besylate Market Industry is expected to grow to 0.65 USD Billion, driven by the healthcare needs of this aging demographic.

The Global Amlodipine Besylate Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.4 USD Billion in 2024, it is anticipated to reach 0.65 USD Billion by 2035, reflecting a compound annual growth rate of 4.49% from 2025 to 2035. This growth trajectory suggests a robust demand for Amlodipine Besylate, driven by factors such as increasing hypertension prevalence, an aging population, and advancements in pharmaceutical research. The market's expansion is indicative of the ongoing need for effective antihypertensive therapies on a global scale.

Increased healthcare expenditure across various regions is a significant driver for the Global Amlodipine Besylate Market Industry. Governments and private sectors are investing more in healthcare infrastructure and services, leading to improved access to medications. This trend is particularly evident in developing countries, where healthcare reforms are underway to enhance treatment accessibility. As healthcare spending rises, the availability of Amlodipine Besylate is expected to improve, thereby expanding its market reach. The anticipated compound annual growth rate of 4.49% from 2025 to 2035 indicates a robust market outlook driven by these financial investments.

The increasing prevalence of hypertension globally is a primary driver for the Global Amlodipine Besylate Market Industry. As more individuals are diagnosed with high blood pressure, the demand for effective antihypertensive medications like Amlodipine Besylate rises. According to health statistics, hypertension affects approximately 1.13 billion people worldwide, leading to a significant market opportunity. The Global Amlodipine Besylate Market Industry is projected to reach 0.4 USD Billion in 2024, reflecting the urgent need for treatment options. This trend indicates a growing awareness of hypertension management, which is likely to bolster market growth in the coming years.

Advancements in pharmaceutical research and development are propelling the Global Amlodipine Besylate Market Industry forward. Continuous innovations in drug formulation and delivery systems enhance the efficacy and safety profiles of Amlodipine Besylate. For instance, the development of extended-release formulations allows for improved patient compliance and better management of blood pressure. These advancements not only improve patient outcomes but also stimulate market growth. The Global Amlodipine Besylate Market Industry is likely to benefit from these innovations, as they align with the increasing demand for more effective treatment options.

Growing awareness of cardiovascular health among the global population is fostering demand for Amlodipine Besylate. Public health campaigns and educational initiatives are increasingly emphasizing the importance of managing blood pressure and preventing cardiovascular diseases. This heightened awareness leads to more individuals seeking medical advice and treatment options, including Amlodipine Besylate. As a result, the Global Amlodipine Besylate Market Industry is likely to see sustained growth, as patients become more proactive in managing their health. The combination of education and accessibility is expected to drive market expansion in the coming years.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Amlodipine Besylate market in North America can be attributed to several key factors. Amlodipine besylate is primarily applied for hypertension treatment and particular chest pain known as angina. Because of the increasing number of cardiovascular diseases in North America, more and more people need a kind of medication like amlodipine besylate to manage their condition.

During these 33 seconds, another person dies of cardiovascular disease in the United States. 695,000 people in the United States died of heart disease in 2021, 1 in every 5 fatalities. Heart disease expenditures represented roughly $239.9 billion for the US during the 2018 - 2019 fiscal year.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Amlodipine Besylate Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's Amlodipine Besylate Market accounts for the second-largest market share as there is increasing attention both from healthcare professionals and among the general public to the problem of prophylaxis and the risks that accompany it. In London, 30% of adults were hypertensive (high blood pressure), while 15% of this group had not been treated. Overall, the rates were more or less the same for both genders. According to age, the figure for total hypertension was 9% for adults aged 16 to 44 years, 54% for 45 to 64 years old, and 60% for adults aged 65 and over.

This increase in awareness has led to the development of more proactive treatment approaches such as medication, for instance, amlodipine besylate. Further, the German Amlodipine Besylate Market held the largest market share, and the UK Amlodipine Besylate Market was the fastest-growing market in the European region.

The Asia-Pacific Amlodipine Besylate Market is expected to grow at the fastest CAGR from 2023 to 2032.

Asia-Pacific's CVDs, including hypertension and coronary artery disease, are becoming more common because of sedentary living habits, unhealthy dietary patterns, and the aging population. The 2022 report called ‘Accidental Deaths & Suicides in India' mentioned the number of heart failure deaths ranging from 25,000 to 28,000 in the last four years. The civic health department, as per the report of 2022, stated that cardiovascular conditions were the reason behind every fourth death in Mumbai. The number of deaths was 94,500 in the city, inclusive of all the cases, with 25% of the entire deaths attributed to heart diseases and hypertension. Amlodipine besylate, a medication used to control hypertension and other cardiovascular diseases, has increased the demand for this medication.

Moreover, China’s Amlodipine Besylate Market held the largest market share, and the Indian Amlodipine Besylate Market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the Amlodipine Besylate market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Amlodipine Besylate industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Amlodipine Besylate industry to benefit clients and increase the market sector. In recent years, the Amlodipine Besylate industry has offered some of the most significant advantages to the healthcare sector. Major players in the Amlodipine Besylate Market, including Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals, are attempting to increase market demand by investing in research and development operations.

Pfizer focuses on finding, developing, making, and selling biopharmaceuticals. The company has drugs for cardiovascular, metabolic, or pain problems, women’s health, cancer, inflammation, diseases, and rare elements of the immune system. It additionally offers sterilized injectable pharmaceuticals, biosimilars, and active pharmaceutical ingredients (API), as well as contract manufacturing services. Pfizer sells its products through wholesalers, drug stores, hospitals, private providers' offices, clinics, government agencies, and drug stores. Its main manufacturing plants are in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the United States. The company has already served the category in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer, the US, is headquartered in New York.

Cipla is a company that produces and markets branded medicines, generics, and active pharmaceutical ingredients (APIs). It provides the solution in the areas of cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and female urologic diseases, osteoporosis, and women's health. The company's medical supplies division expands into consumer healthcare and biosimilar firms. Cipla is engaged in the production of metered-dose inhalers, spacers, and other devices; it also engages in the research and development of new medicines and drug delivery systems. The Company operates in India, the US, Canada, South Africa, and other major regulated and emerging markets. Cipla is headquartered in Mumbai, which is in Maharashtra, India.